Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
ESMO Open|June 4, 2023
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trialG Stocker, S Lorenzen, T Ettrich, et al.
Leukemia Research|January 21, 2015
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome predictionF Ramos, S Thépot, L Pleyer, et al.
British Journal of Cancer|March 21, 2013
Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trialG Pfeiler, H Stöger, P Dubsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2012
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancerP Dubsky, M Filipits, R Jakesz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2022
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studyL Gianni, C S Huang, D Egle, et al.
British Journal of Cancer|October 26, 2013
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patientsP Dubsky, J C Brase, R Jakesz, et al.
Leukemia Research|January 1, 1997
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II studyJ Thaler, W Hilbe, U Apfelbeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2023
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin's lymphoma: results from the randomized international GHSG HD18 trialJ Ferdinandus, H Müller, C Damaschin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)M Moehler, A Maderer, P C Thuss-Patience, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2013
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)G G Steger, R Greil, A Lang, et al.
Pageof 12